Takeda Pharmaceutical/$TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Tokyo, Japan
Employees
49,281
ISIN
US8740602052
Website
TAK Metrics
BasicAdvanced
$47B
32.09
$0.47
0.26
$0.51
3.54%
Price and volume
Market cap
$47B
Beta
0.26
52-week high
$15.43
52-week low
$12.58
Average daily volume
2.1M
Dividend rate
$0.51
Financial strength
Current ratio
1.006
Quick ratio
0.443
Long term debt to equity
65.127
Total debt to equity
73.042
Dividend payout ratio (TTM)
280.28%
Interest coverage (TTM)
4.15%
Management effectiveness
Return on assets (TTM)
1.91%
Return on equity (TTM)
1.52%
Valuation
Price to earnings (TTM)
32.089
Price to revenue (TTM)
0.744
Price to book
0.98
Price to tangible book (TTM)
-3.35
Price to free cash flow (TTM)
4.802
Dividend yield (TTM)
3.35%
Forward dividend yield
3.54%
Growth
Revenue change (TTM)
7.45%
Earnings per share change (TTM)
-26.25%
3-year revenue growth (CAGR)
8.68%
3-year earnings per share growth (CAGR)
-22.76%
3-year dividend per share growth (CAGR)
2.88%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Business Wire·22 hours ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Business Wire·3 days ago
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $47B as of June 04, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 32.09 as of June 04, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of June 04, 2025, the dividend rate is $0.50554 and the yield is 3.54%. Takeda Pharmaceutical has a payout ratio of 280.28% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.